HK inno.N has entered a partnership with Atomatrix to leverage AI in the development of innovative obesity treatments.
This collaboration aims to explore small-molecule candidates that utilize new mechanisms of action, moving away from the prevalent incretin-based therapies in the obesity market. HK inno.N will handle drug synthesis and biological evaluation, focusing on the efficacy and safety of the compounds, while Atomatrix will utilize its proprietary CANDDIE platform for molecule design and screening. This platform integrates AI with molecular dynamics simulations to enhance drug design by optimizing binding stability and pharmacological activity, thus potentially shortening development timelines.
As HK inno.N seeks to diversify its portfolio beyond incretin-based medications—known for side effects like gastrointestinal discomfort and muscle loss—this partnership represents a strategic shift towards developing therapeutics that can better address the challenges faced by current obesity treatments. Park Byung-chul, head of HK inno.N’s New Drug Research Institute, emphasized the goal of identifying promising candidates for expedited development.
Atomatrix's CEO, Lee Eun-ho, highlighted the importance of combining data-driven analysis with physics-based simulations to tackle complex biological targets effectively. This innovative approach could pave the way for more effective obesity treatments in the future.